Nutriband Inc (NTRB)
Nutriband Inc. is a healthcare company focused on developing transdermal pharmaceutical products in the United States. Its main product candidate is AVERSA fentanyl, an abuse-deterrent fentanyl transdermal system designed to deliver extended-release therapy for patients with chronic pain requiring continuous opioid treatment. The company is also advancing AVERSA buprenorphine and AVERSA methylphenidate, along with other transdermal drug products. Nutriband has a commercial development and clinical supply agreement with Kindeva Drug Delivery. Incorporated in 2016, the company is headquartered in Orlando, Florida.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-NTRB
|
$10.23
|
51.3% Upside
|
Bargain
|
$15
|
121.9% Upside
|
Bargain
|
Fair
|
0.0%
|
September 30, 2026
|
17.7x
|
58.4x
|
82.172 M
|
91.251 M
|
0.2%
|
43.4%
|
37.5
|
52.2%
|